Clinical Trial Update: Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial exploring regorafenib plus tislelizumab as first-line systemic therapy for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Regorafenib (regorafenib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN